Masayuki Takeda
Kindai University
144 Papers
747 Citations
Masayuki Takeda is an academic researcher from Kindai University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 33, co-authored 143 publications.
Chat about Author
Papers
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.
Koji Haratani,Hidetoshi Hayashi,Yasutaka Chiba,Keita Kudo,Kimio Yonesaka,Ryoji Kato,Hiroyasu Kaneda,Yoshikazu Hasegawa,Kaoru Tanaka,Masayuki Takeda,Kazuhiko Nakagawa +10 more
TL;DR: Development of irAEs was associated with survival outcome of nivolumab treatment in patients with advanced or recurrent NSCLC, andMultivariable analysis revealed that iraes were positively associated with Survival outcome, with hazard ratios of 0.525 and 0.282.
899
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
Kimio Yonesaka,Kreshnik Zejnullahu,Isamu Okamoto,Taroh Satoh,Federico Cappuzzo,John Souglakos,Dalia Ercan,Andrew H. Rogers,Massimo Roncalli,Masayuki Takeda,Yasuhito Fujisaka,Juliet Philips,Toshio Shimizu,Osamu Maenishi,Yonggon Cho,Jason Sun,Annarita Destro,Koichi Taira,Koji Takeda,Takafumi Okabe,Jeffrey Swanson,Hiroyuki Itoh,Minoru Takada,Eugene Lifshits,Kiyotaka Okuno,Jeffrey A. Engelman,Ramesh A. Shivdasani,Ramesh A. Shivdasani,Kazuto Nishio,Masahiro Fukuoka,Marileila Varella-Garcia,Kazuhiko Nakagawa,Pasi A. Jänne,Pasi A. Jänne +33 more
TL;DR: Examination of cellular data with patient experience improves confidence that concomitant treatment of certain lung, head and neck, or colorectal cancers with cetuximab and an anti-ERBB2 drug may prevent or delay the development of drug resistance.
653
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
Koji Haratani,Hidetoshi Hayashi,Tae Tanaka,Hiroyasu Kaneda,Yosuke Togashi,Kazuko Sakai,Ken-ichiro Hayashi,Shuta Tomida,Yasutaka Chiba,Kimio Yonesaka,Yoshikane Nonagase,Takayuki Takahama,Junko Tanizaki,Kaoru Tanaka,Takeshi Yoshida,K. Tanimura,Masayuki Takeda,Hiroshige Yoshioka,Tadashi Ishida,Tetsuya Mitsudomi,Kazuto Nishio,Kazuhiko Nakagawa +21 more
TL;DR: T790M-negative patients with EGFR mutation-positive non-small-cell lung cancer patients with different mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) are more likely to benefit from nivolumab after EGFR-TKI treatment, possibly as a result of a higher PD-L1 expression level, than are T790m-positive patients.
277
Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab
Junko Tanizaki,Koji Haratani,Hidetoshi Hayashi,Yasutaka Chiba,Yasushi Nakamura,Kimio Yonesaka,Keita Kudo,Hiroyasu Kaneda,Yoshikazu Hasegawa,Kaoru Tanaka,Masayuki Takeda,Akihiko Ito,Kazuhiko Nakagawa +12 more
TL;DR: A baseline signature of a low ANC, high ALC, and high AEC was associated with a better outcome of nivolumab treatment, with the number of favorable factors identifying subgroups of patients differing in survival and response rate.
219
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer.
Kohsuke Isomoto,Koji Haratani,Hidetoshi Hayashi,Shigeki Shimizu,Shuta Tomida,Takashi Niwa,Toshihide Yokoyama,Yasushi Fukuda,Yasutaka Chiba,Ryoji Kato,Junko Tanizaki,Kaoru Tanaka,Masayuki Takeda,Takashi Ogura,Tadashi Ishida,Akihiko Ito,Kazuhiko Nakagawa +16 more
TL;DR: EGFR-TKI treatment was associated with changes in the TME of EGFR-mutated NSCLC, and such changes may provide clues for optimization of subsequent PD-1 inhibitor treatment.